|
We’ve made tremendous progress in breast cancer research in the last 20 years with advances in targeted therapies like Herceptin (and other Her2-targeted therapies) newly approved CDK4/6 inhibitors (Ibrance, Verzinio, Kisqali) for advanced breast cancer, the use of adjuvant (systemic) therapy to reduce risk of recurrence, and genetic tests that allow us to better predict risk and risk of recurrence.
These advances are evidenced in a nearly 40% decrease in breast cancer-related deaths in the last 30 years and more than 3.5 million women and men with a history of breast cancer in the US. Whil
|
